Exchange: NASDAQ·Updated 12:00 AM EST

LVTX LAVA Therapeutics NV

$1.74
$0.00
(0.00%)
Pre-Market
Prev Close $1.74
Reported EarningsAug 13
Mkt Cap$45.77M
Vol285,521.00

About LVTX

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
54

Neutral Sentiment

How do you feel about LVTX?

Advertisement|Remove ads.